ESC TV Today – Your Cardiovascular News

Join interventional cardiologist Davide Capodanno, who reviews the latest TAVI evidence, including durability and risks for younger patients. Cardiac electrophysiologist Fleur Tjong discusses the role of wearables and AI in ECGs, highlighting how these tools can refine device therapy decisions. Cardiology commentator JP Carpenter provides summaries of recent cardiovascular studies, addressing the implications for statins and exercise. The panel also explores intriguing links between gratitude and heart health.

In this engaging discussion, Steffen Massberg, a leading cardiologist from Ludwig Maximilians University Hospital, dives into dual antiplatelet therapy (DAPT). He highlights how about 40% of patients meet high bleeding risk criteria and discusses the implications for shortening DAPT duration. Massberg reviews evidence from key trials supporting shorter therapies and emphasizes the importance of individualized strategies. He also addresses barriers like physician fears regarding stent thrombosis while advocating for advanced imaging techniques to enhance decision-making in DAPT.

Steffen Massberg, a cardiology expert, discusses the nuances of dual antiplatelet therapy duration and strategies tailored for high bleeding-risk patients. He emphasizes the safety of shorter DAPT in complex cases. Joining him is Prash Sanders, a cardiac electrophysiologist, who delves into the obesity-related mechanisms that contribute to atrial fibrillation, highlighting the significance of weight loss thresholds for reducing AF risk. Both guests stress the importance of proactive risk management in improving heart health outcomes.

Folkert Asselbergs, Professor of Cardiology and digital health expert, dives into the transformative role of large language models in clinical settings. He discusses how these models can automate administrative tasks and even serve as AI companions grounded in ESC guidelines. Folkert addresses concerns about hallucinations and bias, and argues for innovative evaluation methods over traditional trials. He encourages democratized patient access to AI tools while emphasizing data security and the potential for personal health apps in the future.

Folkert Asselbergs, a cardiologist and expert in digital health and AI, discusses the implications of large language models (LLMs) in clinical settings, including their role in patient engagement and reducing clinician workload. Massimo Imazio, chair of the upcoming ESC guidelines on myocarditis, delves into the nuances of diagnosing myocarditis, emphasizing cardiac MRI and biopsies when necessary. He also provides critical insights on managing immune-related myocarditis and guidelines for returning patients to physical activity.

In this insightful discussion, Erik Stroes, an academic clinician from Amsterdam University Medical Center with expertise in lipid disorders, delves into the significance of Lp(a) in cardiovascular health. He highlights how elevated Lp(a) is prevalent yet often overlooked in risk assessments. Erik explains the limited impact of lifestyle changes and current medications on lowering Lp(a), and he emphasizes the need for routine testing to enhance risk prediction. He also shares insights on the clinical significance of Lp(a)-lowering therapies and their prioritization in high-risk patients.

Erik Stroes, a leading cardiologist from Amsterdam, dives into the intricate biology of Lp(a) and highlights emerging therapies set to transform cardiovascular care. Vijay Kunadian, an expert in treating older and frail patients, discusses nuanced management strategies for myocardial infarction. They debate the importance of screening for Lp(a) and weigh the benefits of invasive versus conservative approaches for older adults. JP Carpenter contributes a witty 'Mythbusters' segment, debunking common beliefs about beetroot’s impact on heart health.

In this engaging discussion, cardiology specialist Stephanie Schwarting, affiliated with renowned institutions in Munich and Heidelberg, shares her expertise on arrhythmias within cardiac amyloidosis. She delves into the complexities of rate control influenced by heart rate dependence and autonomic dysfunction. The conversation covers the challenges of ablation based on disease stage and the unpredictable progression of conduction disease. Schwarting also emphasizes the importance of individualized monitoring strategies and the role of multidisciplinary teams in enhancing patient care.

Stephanie Schwarting, a cardiac amyloidosis expert from University Hospital Munich, dives into arrhythmias in transthyretin cardiac amyloidosis, discussing management strategies and the nuances of treating atrial fibrillation in this context. Ahmad Masri, a cardiologist specializing in hypertrophic cardiomyopathy from Oregon Health & Science University, explores the complexities of managing LVOT obstruction and the role of myosin inhibitors versus traditional therapies. Both guests provide invaluable insights into cutting-edge treatments and patient management approaches.

Join cardiologist Milton Packer as he dives into the critical role of visceral adiposity in managing heart failure with preserved ejection fraction (HFpEF). He explores how SGLT2 inhibitors and GLP-1 agonists shift adipose biology towards a protective state, challenging traditional views. The integration of artificial intelligence in echocardiography systems is also discussed, highlighting its potential for early disease detection and the importance of training on diverse populations to avoid bias. Packer's insights signal a pivotal shift in cardiovascular treatment strategies.